136 related articles for article (PubMed ID: 26689650)
1. Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis.
Ochi Y; Hiramoto N; Ono Y; Yoshioka S; Tabata S; Yonetani N; Matsushita A; Imai Y; Ishikawa T
Leuk Lymphoma; 2016 Aug; 57(8):1945-8. PubMed ID: 26689650
[No Abstract] [Full Text] [Related]
2. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
3. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
[No Abstract] [Full Text] [Related]
5. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
Chan TS; Khong PL; Kwong YL
Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
[No Abstract] [Full Text] [Related]
6. Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy.
Rozman S; Sonc M; Novakovic BJ
Leuk Lymphoma; 2012 Oct; 53(10):1945-8. PubMed ID: 22563814
[TBL] [Abstract][Full Text] [Related]
7. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.
Schwarzbich MA; Schöning T; Cremer M; Lisenko K; Ho AD; Witzens-Harig M
Leuk Lymphoma; 2016 Jul; 57(7):1723-6. PubMed ID: 26980422
[No Abstract] [Full Text] [Related]
10. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
[TBL] [Abstract][Full Text] [Related]
11. BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.
Palickova M; Mocikova H; Vernerova Z; Campr V; Kozak T
Leuk Lymphoma; 2013 Sep; 54(9):2081-2. PubMed ID: 23311295
[No Abstract] [Full Text] [Related]
12. Partial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP.
Feldmann G; Nattermann J; Gerhardt T; Nähle CP; Spengler U; Woitas R
Int J Lab Hematol; 2007 Dec; 29(6):469-73. PubMed ID: 17988304
[TBL] [Abstract][Full Text] [Related]
13. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T
Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
[No Abstract] [Full Text] [Related]
14. Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study.
Barnes JA; Redd R; Fisher DC; Hochberg EP; Takvorian T; Neuberg D; Jacobsen E; Abramson JS
Hematol Oncol; 2018 Oct; 36(4):633-637. PubMed ID: 29956350
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous Presence of Follicular Lymphoma, Diffuse Large B-cell Lymphoma, and Hodgkin-like Lymphoma.
Papoudou-Bai A; Marinos L; Papathanasiou K; Kanavaros P; Kapsali E
Turk J Haematol; 2018 Nov; 35(4):308-309. PubMed ID: 30398157
[No Abstract] [Full Text] [Related]
16. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
17. Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy.
Mercadal S; Pomares H; Sancho JM; Climent F; García O; Encuentra M; Domingo-Doménech E; Sorigué M; Moreno M; Oliveira AC; Ribera JM; Fernández de Sevilla A; González-Barca E
Br J Haematol; 2016 Feb; 172(3):470-3. PubMed ID: 26010479
[No Abstract] [Full Text] [Related]
18. FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma.
Fabisiewicz A; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Siedlecki JA
Leuk Lymphoma; 2011 Aug; 52(8):1604-6. PubMed ID: 21657954
[No Abstract] [Full Text] [Related]
19. Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma.
Cho H; Yoon DH; Kim JH; Ko YB; Kwon BS; Song IH; Suh C
Korean J Intern Med; 2016 May; 31(3):605-7. PubMed ID: 26968186
[No Abstract] [Full Text] [Related]
20. A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
Bari A; Marcheselli R; Marcheselli L; Alvarez I; Pozzi S; Ferri P; Lazzaro A; Fragasso A; Neri S; Baldini L; Carella AM; Angrilli F; Guariglia R; Buda G; Stelitano C; Sacchi S;
Acta Haematol; 2017; 137(1):7-14. PubMed ID: 27820922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
